Synopsis
Synopsis
0
JDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
Annual Reports
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 3-((1r,2r)-3-(dimethylamino)-1-ethyl-2-methylpropyl)phenol
2. Nucynta
3. Tapentadol
1. 175591-09-0
2. Tapentadol Hcl
3. Nucynta
4. Palexia
5. Tapentadol (hydrochloride)
6. Nucynta Er
7. Bn-200 Hydrochloride
8. Cg5503 Hydrochloride
9. Cg-5503 Hydrochloride
10. 3-((2r,3r)-1-(dimethylamino)-2-methylpentan-3-yl)phenol Hydrochloride
11. 71204kii53
12. 175591-09-0 (hcl)
13. Tapentadol Hydrochloride (jan)
14. Tapentadol Hydrochloride [jan]
15. 3-[(1r,2r)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol Hydrochloride
16. Palexia Retard
17. 3-((1r,2r)-3-(dimethylamino)-1-ethyl-2-methylpropyl)phenol Hydrochloride
18. Unii-71204kii53
19. Palexia Sr
20. Phenol, 3-[(1r,2r)-3-(dimethylamino)-1-ethyl-2-methylpropyl]-, Hydrochloride (1:1)
21. Phenol, 3-((1r,2r)-3-(dimethylamino)-1-ethyl-2-methylpropyl)-, Hydrochloride (1:1)
22. Nucynta (tn)
23. Schembl238138
24. Jns-024 Er
25. Chembl1201777
26. Dtxsid00938677
27. Amy25232
28. Hy-70042a
29. Mfcd00944992
30. Tapentadol Hydrochloride [mi]
31. Akos016842888
32. Cs-0879
33. Tapentadol Hydrochloride [mart.]
34. Tapentadol Hydrochloride [vandf]
35. Tapentadol Hydrochloride [who-dd]
36. Ac-32018
37. Tapentadol Hydrochloride [orange Book]
38. D10199
39. Tapentadol Hydrochloride [ep Monograph]
40. 591t238
41. Tapentadol Hydrochloride (1.0 Mg/ml In Methanol)
42. R-331333
43. Q27265914
44. 3-((1r,2r)-3-(dimethylamino)-1-ethyl-2-methylpropyl) Phenol Hydrochloride
45. 3-((1r,2r)-3-(dimethylamino)-1-ethyl-2-methylpropyl)-phenol Hydrochloride
46. 3-[(2r,3r)-1-(dimethylamino)-2-methylpentan-3-yl]phenol;hydrochloride
47. 3-[1-(dimethylamino)-2-methylpentan-3-yl]phenol--hydrogen Chloride (1/1)
48. (-)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol Hydrochloride
49. (-)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol Hydrochloride
50. 3-[(1r,2r)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol Monohydrochloride
51. Phenol, 3-((1r,2r)-3-(dimethylamino)-1-ethyl-2-methylpropyl)-, Hydrochloride
52. Phenol, 3-(3-(dimethylamino)-1-ethyl-2-methylpropyl)-, Hydrochloride, (r-(r*,r*))-
53. Tapentadol Hydrochloride Solution, 1.0 Mg/ml In Methanol (as Free Base), Ampule Of 1 Ml, Certified Reference Material
Molecular Weight | 257.80 g/mol |
---|---|
Molecular Formula | C14H24ClNO |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 5 |
Exact Mass | 257.1546421 g/mol |
Monoisotopic Mass | 257.1546421 g/mol |
Topological Polar Surface Area | 23.5 Ų |
Heavy Atom Count | 17 |
Formal Charge | 0 |
Complexity | 193 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Nucynta |
PubMed Health | Tapentadol (By mouth) |
Drug Classes | Analgesic |
Drug Label | NUCYNTA ER (tapentadol) is a mu-opioid receptor agonist, supplied in extended-release film-coated tablets for oral administration, containing 58.24, 116.48, 174.72, 232.96, and 291.20 mg of tapentadol hydrochloride in each tablet strength, correspo... |
Active Ingredient | Tapentadol hydrochloride |
Dosage Form | Tablet; Solution |
Route | Oral |
Strength | eq 100mg base; eq 50mg base; eq 75mg base; eq 20mg base/ml |
Market Status | Prescription |
Company | Janssen Pharms |
2 of 4 | |
---|---|
Drug Name | Nucynta er |
Drug Label | NUCYNTA ER (tapentadol) is a mu-opioid receptor agonist, supplied in extended-release film-coated tablets for oral administration, containing 58.24, 116.48, 174.72, 232.96, and 291.20 mg of tapentadol hydrochloride in each tablet strength, correspo... |
Active Ingredient | Tapentadol hydrochloride |
Dosage Form | Tablet, extended release |
Route | Oral |
Strength | eq 100mg base; eq 50mg base; eq 250mg base; eq 150mg base; eq 200mg base |
Market Status | Prescription |
Company | Janssen Pharms |
3 of 4 | |
---|---|
Drug Name | Nucynta |
PubMed Health | Tapentadol (By mouth) |
Drug Classes | Analgesic |
Drug Label | NUCYNTA ER (tapentadol) is a mu-opioid receptor agonist, supplied in extended-release film-coated tablets for oral administration, containing 58.24, 116.48, 174.72, 232.96, and 291.20 mg of tapentadol hydrochloride in each tablet strength, correspo... |
Active Ingredient | Tapentadol hydrochloride |
Dosage Form | Tablet; Solution |
Route | Oral |
Strength | eq 100mg base; eq 50mg base; eq 75mg base; eq 20mg base/ml |
Market Status | Prescription |
Company | Janssen Pharms |
4 of 4 | |
---|---|
Drug Name | Nucynta er |
Drug Label | NUCYNTA ER (tapentadol) is a mu-opioid receptor agonist, supplied in extended-release film-coated tablets for oral administration, containing 58.24, 116.48, 174.72, 232.96, and 291.20 mg of tapentadol hydrochloride in each tablet strength, correspo... |
Active Ingredient | Tapentadol hydrochloride |
Dosage Form | Tablet, extended release |
Route | Oral |
Strength | eq 100mg base; eq 50mg base; eq 250mg base; eq 150mg base; eq 200mg base |
Market Status | Prescription |
Company | Janssen Pharms |
Treatment of acute pain
Treatment of acute pain
Treatment of acute pain
Treatment of chronic pain
Treatment of chronic pain
Treatment of acute pain
Treatment of chronic pain
Adrenergic Uptake Inhibitors
Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin. (See all compounds classified as Adrenergic Uptake Inhibitors.)
Analgesics, Opioid
Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. (See all compounds classified as Analgesics, Opioid.)
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
(2S, 3R)-1-(Dimethylamino)-3-(3-methoxyphenyl)-2-m...
CAS Number : 809282-20-0
End Use API : Tapentadol
About The Company : Cohance Lifesciences is a leading CDMO and API platform, offering products and services across all phases of a molecule’s lifecycle from development to commer...
CAS Number : 37951-49-8
End Use API : Tapentadol
About The Company : Cohance Lifesciences is a leading CDMO and API platform, offering products and services across all phases of a molecule’s lifecycle from development to commer...
CAS Number : 37951-49-8
End Use API : Tapentadol
About The Company : Sanika Chemicals Pvt. Ltd. is the fast growing company establishing a strong presence in the Domestic as well Global market as a reliable partner. We are very m...
(-)-Dibenzoyl-L-tartaric acid (DBLT)
CAS Number : 62708-56-9
End Use API : Tapentadol
About The Company : Scimplify is a science-first company specializing in end-to-end development and manufacturing of specialty chemicals. We support the entire product life cycle, ...
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
66
PharmaCompass offers a list of Tapentadol API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Tapentadol manufacturer or Tapentadol supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Tapentadol manufacturer or Tapentadol supplier.
PharmaCompass also assists you with knowing the Tapentadol API Price utilized in the formulation of products. Tapentadol API Price is not always fixed or binding as the Tapentadol Price is obtained through a variety of data sources. The Tapentadol Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Palexia manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Palexia, including repackagers and relabelers. The FDA regulates Palexia manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Palexia API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Palexia manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Palexia supplier is an individual or a company that provides Palexia active pharmaceutical ingredient (API) or Palexia finished formulations upon request. The Palexia suppliers may include Palexia API manufacturers, exporters, distributors and traders.
click here to find a list of Palexia suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Palexia DMF (Drug Master File) is a document detailing the whole manufacturing process of Palexia active pharmaceutical ingredient (API) in detail. Different forms of Palexia DMFs exist exist since differing nations have different regulations, such as Palexia USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Palexia DMF submitted to regulatory agencies in the US is known as a USDMF. Palexia USDMF includes data on Palexia's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Palexia USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Palexia suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Palexia Drug Master File in Korea (Palexia KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Palexia. The MFDS reviews the Palexia KDMF as part of the drug registration process and uses the information provided in the Palexia KDMF to evaluate the safety and efficacy of the drug.
After submitting a Palexia KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Palexia API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Palexia suppliers with KDMF on PharmaCompass.
A Palexia CEP of the European Pharmacopoeia monograph is often referred to as a Palexia Certificate of Suitability (COS). The purpose of a Palexia CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Palexia EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Palexia to their clients by showing that a Palexia CEP has been issued for it. The manufacturer submits a Palexia CEP (COS) as part of the market authorization procedure, and it takes on the role of a Palexia CEP holder for the record. Additionally, the data presented in the Palexia CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Palexia DMF.
A Palexia CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Palexia CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Palexia suppliers with CEP (COS) on PharmaCompass.
A Palexia written confirmation (Palexia WC) is an official document issued by a regulatory agency to a Palexia manufacturer, verifying that the manufacturing facility of a Palexia active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Palexia APIs or Palexia finished pharmaceutical products to another nation, regulatory agencies frequently require a Palexia WC (written confirmation) as part of the regulatory process.
click here to find a list of Palexia suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Palexia as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Palexia API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Palexia as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Palexia and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Palexia NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Palexia suppliers with NDC on PharmaCompass.
Palexia Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Palexia GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Palexia GMP manufacturer or Palexia GMP API supplier for your needs.
A Palexia CoA (Certificate of Analysis) is a formal document that attests to Palexia's compliance with Palexia specifications and serves as a tool for batch-level quality control.
Palexia CoA mostly includes findings from lab analyses of a specific batch. For each Palexia CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Palexia may be tested according to a variety of international standards, such as European Pharmacopoeia (Palexia EP), Palexia JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Palexia USP).